| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| EBL (ml), median (i.q.r.) | 600 (363–935) | 580 (400–890) | 610 (420–945) | 0.515 |
| Operating time (min), median (i.q.r.) | 526 (450–622) | 519 (447–603) | 532 (450–532) | 0.353 |
| Blood transfusion | 16 (7.9) | 9 (11.4) | 7 (5.6) | 0.182 |
| Major morbidity rate | 46 (22.7) | 24 (30.4) | 22 (17.7) | 0.040 |
| POPF grade B/C§ | 33 (16.3) | 20 (25.3) | 13 (10.5) | 0.006 |
| PPH grade B/C§ | 9 (4.4) | 3 (3.8) | 6 (4.8) | 0.182 |
| DGE grade B/C§ | 36 (17.7) | 20 (25.3) | 16 (12.9) | 0.037 |
| Diarrhoea | 41 (20.2) | 14 (17.7) | 27 (21.8) | 0.591 |
| Respiratory | 6 (3.0) | 1 (1.3) | 5 (4.0) | 0.408 |
| Cardiac | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| Liver failure | 3 (1.5) | 2 (2.5) | 1 (0.8) | 0.561 |
| Deep vien thrombosis/pulmonary embolism | 2 (1.0) | 0 | 2 (1.6) | 0.522 |
| PVT | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| SSI | 27 (13.3) | 15 (19.0) | 12 (9.7) | 0.088 |
| Reoperation on | 8 (3.9) | 5 (6.3) | 3 (2.4) | 0.266 |
| ICU admission | 6 (3.0) | 0 | 6 (4.8) | 0.084 |
| Hospital stay (days), median (i.q.r.) | 27 (19–37) | 34 (23–41) | 24 (17–33) | 0.002 |
| Readmission | 21 (10.3) | 8 (10.1) | 13 (10.5) | >0.999 |
| 90-day mortality rate | 1 (0.5) | 0 | 1 (0.8) | >0.999 |
| Use of adjuvant chemotherapy | 164 (80.8) | 64 (81.0) | 101 (81.5) | >0.999 |
| Regimen of adjuvant chemotherapy | <0.001 | |||
| S-1 | 120 (59.1) | 32 (40.5) | 89 (71.8) | |
| Gemcitabine | 29 (14.3) | 27 (34.2) | 2 (1.6) | |
| Others | 15 (7.4) | 5 (6.3) | 10 (8.1) |
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| EBL (ml), median (i.q.r.) | 600 (363–935) | 580 (400–890) | 610 (420–945) | 0.515 |
| Operating time (min), median (i.q.r.) | 526 (450–622) | 519 (447–603) | 532 (450–532) | 0.353 |
| Blood transfusion | 16 (7.9) | 9 (11.4) | 7 (5.6) | 0.182 |
| Major morbidity rate | 46 (22.7) | 24 (30.4) | 22 (17.7) | 0.040 |
| POPF grade B/C§ | 33 (16.3) | 20 (25.3) | 13 (10.5) | 0.006 |
| PPH grade B/C§ | 9 (4.4) | 3 (3.8) | 6 (4.8) | 0.182 |
| DGE grade B/C§ | 36 (17.7) | 20 (25.3) | 16 (12.9) | 0.037 |
| Diarrhoea | 41 (20.2) | 14 (17.7) | 27 (21.8) | 0.591 |
| Respiratory | 6 (3.0) | 1 (1.3) | 5 (4.0) | 0.408 |
| Cardiac | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| Liver failure | 3 (1.5) | 2 (2.5) | 1 (0.8) | 0.561 |
| Deep vien thrombosis/pulmonary embolism | 2 (1.0) | 0 | 2 (1.6) | 0.522 |
| PVT | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| SSI | 27 (13.3) | 15 (19.0) | 12 (9.7) | 0.088 |
| Reoperation on | 8 (3.9) | 5 (6.3) | 3 (2.4) | 0.266 |
| ICU admission | 6 (3.0) | 0 | 6 (4.8) | 0.084 |
| Hospital stay (days), median (i.q.r.) | 27 (19–37) | 34 (23–41) | 24 (17–33) | 0.002 |
| Readmission | 21 (10.3) | 8 (10.1) | 13 (10.5) | >0.999 |
| 90-day mortality rate | 1 (0.5) | 0 | 1 (0.8) | >0.999 |
| Use of adjuvant chemotherapy | 164 (80.8) | 64 (81.0) | 101 (81.5) | >0.999 |
| Regimen of adjuvant chemotherapy | <0.001 | |||
| S-1 | 120 (59.1) | 32 (40.5) | 89 (71.8) | |
| Gemcitabine | 29 (14.3) | 27 (34.2) | 2 (1.6) | |
| Others | 15 (7.4) | 5 (6.3) | 10 (8.1) |
Values are n (%) unless otherwise stated. *From 2010 through 2015. †From 2016 through 2021. EBL, estimated blood loss. POPF, postoperative pancreatic fistula; §According to International Study Group25–27. PPH, postpancreatectomy haemorrhage; DGE, delayed gastric emptying; PVT, portal vein thrombosis; SSI, surgical site infection; ICU, intensive care unit; S-1, tegafur-gimeracil-oteracil potassium.
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| EBL (ml), median (i.q.r.) | 600 (363–935) | 580 (400–890) | 610 (420–945) | 0.515 |
| Operating time (min), median (i.q.r.) | 526 (450–622) | 519 (447–603) | 532 (450–532) | 0.353 |
| Blood transfusion | 16 (7.9) | 9 (11.4) | 7 (5.6) | 0.182 |
| Major morbidity rate | 46 (22.7) | 24 (30.4) | 22 (17.7) | 0.040 |
| POPF grade B/C§ | 33 (16.3) | 20 (25.3) | 13 (10.5) | 0.006 |
| PPH grade B/C§ | 9 (4.4) | 3 (3.8) | 6 (4.8) | 0.182 |
| DGE grade B/C§ | 36 (17.7) | 20 (25.3) | 16 (12.9) | 0.037 |
| Diarrhoea | 41 (20.2) | 14 (17.7) | 27 (21.8) | 0.591 |
| Respiratory | 6 (3.0) | 1 (1.3) | 5 (4.0) | 0.408 |
| Cardiac | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| Liver failure | 3 (1.5) | 2 (2.5) | 1 (0.8) | 0.561 |
| Deep vien thrombosis/pulmonary embolism | 2 (1.0) | 0 | 2 (1.6) | 0.522 |
| PVT | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| SSI | 27 (13.3) | 15 (19.0) | 12 (9.7) | 0.088 |
| Reoperation on | 8 (3.9) | 5 (6.3) | 3 (2.4) | 0.266 |
| ICU admission | 6 (3.0) | 0 | 6 (4.8) | 0.084 |
| Hospital stay (days), median (i.q.r.) | 27 (19–37) | 34 (23–41) | 24 (17–33) | 0.002 |
| Readmission | 21 (10.3) | 8 (10.1) | 13 (10.5) | >0.999 |
| 90-day mortality rate | 1 (0.5) | 0 | 1 (0.8) | >0.999 |
| Use of adjuvant chemotherapy | 164 (80.8) | 64 (81.0) | 101 (81.5) | >0.999 |
| Regimen of adjuvant chemotherapy | <0.001 | |||
| S-1 | 120 (59.1) | 32 (40.5) | 89 (71.8) | |
| Gemcitabine | 29 (14.3) | 27 (34.2) | 2 (1.6) | |
| Others | 15 (7.4) | 5 (6.3) | 10 (8.1) |
| . | All . | Former period* . | Latter period† . | . |
|---|---|---|---|---|
| . | (n = 203) . | (n = 79) . | (n = 124) . | P . |
| EBL (ml), median (i.q.r.) | 600 (363–935) | 580 (400–890) | 610 (420–945) | 0.515 |
| Operating time (min), median (i.q.r.) | 526 (450–622) | 519 (447–603) | 532 (450–532) | 0.353 |
| Blood transfusion | 16 (7.9) | 9 (11.4) | 7 (5.6) | 0.182 |
| Major morbidity rate | 46 (22.7) | 24 (30.4) | 22 (17.7) | 0.040 |
| POPF grade B/C§ | 33 (16.3) | 20 (25.3) | 13 (10.5) | 0.006 |
| PPH grade B/C§ | 9 (4.4) | 3 (3.8) | 6 (4.8) | 0.182 |
| DGE grade B/C§ | 36 (17.7) | 20 (25.3) | 16 (12.9) | 0.037 |
| Diarrhoea | 41 (20.2) | 14 (17.7) | 27 (21.8) | 0.591 |
| Respiratory | 6 (3.0) | 1 (1.3) | 5 (4.0) | 0.408 |
| Cardiac | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| Liver failure | 3 (1.5) | 2 (2.5) | 1 (0.8) | 0.561 |
| Deep vien thrombosis/pulmonary embolism | 2 (1.0) | 0 | 2 (1.6) | 0.522 |
| PVT | 1 (0.5) | 1 (1.3) | 0 | 0.389 |
| SSI | 27 (13.3) | 15 (19.0) | 12 (9.7) | 0.088 |
| Reoperation on | 8 (3.9) | 5 (6.3) | 3 (2.4) | 0.266 |
| ICU admission | 6 (3.0) | 0 | 6 (4.8) | 0.084 |
| Hospital stay (days), median (i.q.r.) | 27 (19–37) | 34 (23–41) | 24 (17–33) | 0.002 |
| Readmission | 21 (10.3) | 8 (10.1) | 13 (10.5) | >0.999 |
| 90-day mortality rate | 1 (0.5) | 0 | 1 (0.8) | >0.999 |
| Use of adjuvant chemotherapy | 164 (80.8) | 64 (81.0) | 101 (81.5) | >0.999 |
| Regimen of adjuvant chemotherapy | <0.001 | |||
| S-1 | 120 (59.1) | 32 (40.5) | 89 (71.8) | |
| Gemcitabine | 29 (14.3) | 27 (34.2) | 2 (1.6) | |
| Others | 15 (7.4) | 5 (6.3) | 10 (8.1) |
Values are n (%) unless otherwise stated. *From 2010 through 2015. †From 2016 through 2021. EBL, estimated blood loss. POPF, postoperative pancreatic fistula; §According to International Study Group25–27. PPH, postpancreatectomy haemorrhage; DGE, delayed gastric emptying; PVT, portal vein thrombosis; SSI, surgical site infection; ICU, intensive care unit; S-1, tegafur-gimeracil-oteracil potassium.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
